Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade
Juan C. Osorio(Memorial Sloan Kettering Cancer Center), Matthew D. Hellmann(Memorial Sloan Kettering Cancer Center), Darragh Halpenny(Memorial Sloan Kettering Cancer Center), Michelle S. Ginsberg(Memorial Sloan Kettering Cancer Center), Helena A. Yu(Memorial Sloan Kettering Cancer Center), Jennifer N. Durham(Bloomberg (United States)), Barzin Y. Nabet(Gene Therapy Laboratory), Andrew J. Plodkowski(Memorial Sloan Kettering Cancer Center), Kathryn C. Arbour(Memorial Sloan Kettering Cancer Center), Luis A. Díaz(Memorial Sloan Kettering Cancer Center), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Peter Sawan(Memorial Sloan Kettering Cancer Center), Azadeh Namakydoust(Memorial Sloan Kettering Cancer Center), Joseph G. Crompton(Memorial Sloan Kettering Cancer Center), Hira Rizvi(Memorial Sloan Kettering Cancer Center), Jamie E. Chaft(Memorial Sloan Kettering Cancer Center), Dung T. Le(Johns Hopkins University)
Cited by 134
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Cancer Genome Landscapes
|Science|2013|8k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k